Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osilodrostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 known ✓ | P15538 | 7/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 17/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osilodrostat SCHEMBL30395982 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL12460772 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL1037474 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL14761109 | 0.99 | CYP11B2 (0.98) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL16280483 | 0.99 | CYP11B2 (0.98) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL13837602 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL15128942 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL30395736 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1039611 | 0.93 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1040487 | 0.92 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2836228-B1 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2024-03-20 | — | — | EP | claimed |
| US-20200030442-A1 | COMBINATION THERAPIES | CAO ZHU ALEXANDER (US) | 2020-01-30 | — | — | US | claimed |
| US-20170340733-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-11-30 | — | — | US | claimed |
| EP-3233918-A1 | COMBINATION THERAPIES | Novartis AG (CH) | 2017-10-25 | — | — | EP | claimed |
| WO-2016100882-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | claimed |
| US-20160176883-A1 | Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | claimed |
| US-9334276-B2 | Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor | NOVARTIS AG (CH) | 2016-05-10 | — | — | US | claimed |
| US-9333234-B2 | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors | NOVARTIS AG (CH) | 2016-05-10 | — | — | US | claimed |
| EP-2804863-B1 | NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | claimed |
| US-20150087588-A1 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS | NOVATIS AG (CH) | 2015-03-26 | — | — | US | claimed |
| EP-2836228-A1 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS | Novartis AG (CH) | 2015-02-18 | — | — | EP | claimed |
| US-20140364470-A1 | New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor | NOVARTIS AG (CH) | 2014-12-11 | — | — | US | claimed |
| EP-2804863-A1 | NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR | Novartis AG (CH) | 2014-11-26 | — | — | EP | claimed |
| EP-2256118-B1 | Condensed imidazolo derivatives for the inhibition of aromatase and the treatment of aldosterone related diseases | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | claimed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | claimed |
| US-20130287789-A1 | Organic Compounds | NOVARTIS AG (CH) | 2013-10-31 | — | — | US | claimed |
| WO-2013153129-A1 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-17 | — | — | WO | claimed |
| WO-2013109514-A1 | NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR | NOVARTIS AG (CH) | 2013-07-25 | — | — | WO | claimed |
| EP-1919916-B1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | claimed |
| US-8314097-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030442-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | CYP11B1 2056/4885CYP11B2 1506/4885CYP19A1 1005/4885 |
| US-20170340733-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | CYP11B1 2056/4885CYP11B2 1506/4885CYP19A1 1005/4885 |
| US-20140364470-A1 | New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor | CYP19A1, CYP21A2, CYP17A1 | CYP11B1 8/4885CYP11B2 13/4885CYP19A1 1/4885 |
| US-20150087588-A1 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS | SSTR5, CRH, SSTR2 | CYP11B1 9/4885CYP11B2 10/4885CYP19A1 121/4885 |
| US-20160176883-A1 | Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor | CYP21A2, CYP19A1, NR5A1 | CYP11B1 8/4885CYP11B2 15/4885CYP19A1 2/4885 |
| US-20130287789-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B1 5/4885CYP11B2 14/4885CYP19A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.